Publications by authors named "A Turan Ilica"
A 62-year-old man, previously treated for oral cavity carcinoma, presented with new-onset cognitive-motor symptoms. Brain MRI revealed a periventricular, avidly enhancing lesion in the right anterior basal ganglia and hypothalamus suspicious for a brain tumor, particularly CNS lymphoma. 18F-FDG brain PET/CT showed corresponding uptake suggestive of primary brain tumor, lymphoma, or metastasis.
View Article and Find Full Text PDFArticle Synopsis
- The study looked at patients with brain tumors caused by colorectal cancer to see how to better treat and watch them.
- Researchers wanted to find out what factors could help predict how long patients might live and how their tumors might grow after treatment with a specific therapy called stereotactic radiosurgery (SRS).
- The results showed that many patients with these brain tumors also have other cancer spreading in their body, and certain genetic changes in their tumors can help understand how their health might change after treatment.
Article Synopsis
- Reliable AI in medical diagnoses requires effective uncertainty quantification (UQ), but current methods can be impractical for clinical use.
- The proposed UQ approach utilizes deep neuroevolution (DNE) to efficiently create an ensemble of accurate models, particularly analyzing language lateralization maps from rs-fMRI scans.
- Results show that DNE-based UQ aligns well with expert assessments, indicating its potential reliability for identifying uncertainties in medical imaging, especially with out-of-distribution data.
Introduction: Patients with EGFR-mutant NSCLC have a high incidence of brain metastases. The EGFR-directed tyrosine kinase inhibitor osimertinib has intracranial activity, making the role of local central nervous system (CNS)-directed therapies, such as radiation and surgery, less clear.
Methods: Patients with EGFR-mutant NSCLC and brain metastases who received osimertinib as initial therapy after brain metastasis diagnosis were included.
Vaccination-associated adenopathy is a frequent imaging finding after administration of COVID-19 vaccines that may lead to a diagnostic conundrum in patients with manifest or suspected cancer, in whom it may be indistinguishable from malignant nodal involvement. To help the medical community address this concern in the absence of studies and evidence-based guidelines, this special report offers recommendations developed by a multidisciplinary panel of experts from three of the leading tertiary care cancer centers in the United States. According to these recommendations, some routine imaging examinations, such as those for screening, should be scheduled before or at least 6 weeks after the final vaccination dose to allow for any reactive adenopathy to resolve.
View Article and Find Full Text PDF